BW
ENGNW icon

Boaz Weinstein’s enGene Therapeutics Warrants ENGNW Stock Holding History

Boaz Weinstein’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,057
Closed -$101K – 417
2026
Q1 		$101K Sell
40,057
-97,301
-71% -$288K ﹤0.01% 278
2025
Q4 		$391K Sell
137,358
-40,976
-23% -$93.5K 0.01% 218
2025
Q3 		$128K Hold
178,334
– – ﹤0.01% 236
2025
Q2 		$146K Hold
178,334
– – ﹤0.01% 222
2025
Q1 		$111K Hold
178,334
– – ﹤0.01% 160
2024
Q4 		$150K Sell
178,334
-14,000
-7% -$20.7K ﹤0.01% 159
2024
Q3 		$274K Hold
192,334
– – 0.01% 175
2024
Q2 		$248K Sell
192,334
-1,629
-0.8% -$5.21K ﹤0.01% 190
2024
Q1 		$1.01M Sell
193,963
-36,507
-16% -$111K 0.02% 166
2023
Q4 		$271K Buy
+230,470
New +$177K 0.01% 265

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Boaz Weinstein's ENGNW Position: Q2 2026 in Review

Boaz Weinstein sold out of enGene Therapeutics Warrants (ENGNW) in Q2 2026, closing a stake of 40,057 shares — an estimated $101K sold.

Boaz Weinstein first reported a position in ENGNW in Q4 2023 and held it in 10 quarters. The position peaked at $1.01M in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • Boaz Weinstein reported no remaining enGene Therapeutics Warrants position as of Q2 2026 after selling out during the quarter.
  • Boaz Weinstein sold 40,057 enGene Therapeutics Warrants shares in Q2 2026, an estimated $101K.
  • Boaz Weinstein first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 10 quarters.
  • Boaz Weinstein's enGene Therapeutics Warrants position peaked at $1.01M in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Saba Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.